Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05593653 · ClinicalTrials.gov registry record · Phase 4

Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes

A Phase 4 study of Diabetes and Insomnia, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
Phase 4
Development phase
61
Enrollment target
1
Study location

NCT05593653 is a Phase 4 study of Diabetes and Insomnia that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 61 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05593653, a Phase 4 study of Diabetes and Insomnia, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
Phase 4
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

The aim of this study is to determine if suvorexant can help treat the severity of insomnia in midlife women who are pre-diabetic.

Interventions

  • DRUG Placebo
  • DRUG Suvorexant

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2023-01-06
Est. Completion 2025-12-31
Phase Phase 4

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT05593653

The ClinicalTrials.gov registry entry for NCT05593653 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05593653 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05593653 about?

NCT05593653 is a clinical study titled "Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes". The aim of this study is to determine if suvorexant can help treat the severity of insomnia in midlife women who are pre-diabetic.

What is the current status of trial NCT05593653?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2023-01-06. Estimated completion is 2025-12-31.

What conditions does trial NCT05593653 study?

This clinical trial studies the following conditions: Diabetes, Insomnia, Menopause.

What interventions are being tested in trial NCT05593653?

The interventions under investigation include: Placebo (DRUG), Suvorexant (DRUG).

Who is sponsoring clinical trial NCT05593653?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05593653 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.